The stock of BioAffinity Technologies Inc (BIAF) has seen a 16.64% increase in the past week, with a 19.05% gain in the past month, and a -50.98% decrease in the past quarter. The volatility ratio for the week is 21.18%, and the volatility levels for the past 30 days are at 15.68% for BIAF. The simple moving average for the past 20 days is 19.69% for BIAF’s stock, with a -59.56% simple moving average for the past 200 days.
Is It Worth Investing in BioAffinity Technologies Inc (NASDAQ: BIAF) Right Now?
Moreover, the 36-month beta value for BIAF is 2.52. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BIAF is 20.25M and currently, short sellers hold a 3.80% of that float. On July 09, 2025, BIAF’s average trading volume was 6.96M shares.
BIAF) stock’s latest price update
BioAffinity Technologies Inc (NASDAQ: BIAF)’s stock price has soared by 14.30% in relation to previous closing price of $0.29. Nevertheless, the company has seen a gain of 16.64% in its stock price over the last five trading days. businesswire.com reported 2025-06-26 that SAN ANTONIO–(BUSINESS WIRE)– #BIAF–bioAffinity scientists present breakthrough research on using siRNAs to knock down two receptors on the cell membrane to selectively kill cancer cells.
BIAF Trading at 13.81% from the 50-Day Moving Average
After a stumble in the market that brought BIAF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.79% of loss for the given period.
Stock Fundamentals for BIAF
Current profitability levels for the company are sitting at:
- -1.09 for the present operating margin
- 0.34 for the gross margin
The net margin for BioAffinity Technologies Inc stands at -1.11. The total capital return value is set at -4.52. Equity return is now at value -290.85, with -143.25 for asset returns.
Based on BioAffinity Technologies Inc (BIAF), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -4.93. The debt to equity ratio resting at 0.92. The interest coverage ratio of the stock is -114.15.
Currently, EBITDA for the company is -8.33 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 1.18. The receivables turnover for the company is 9.14for trailing twelve months and the total asset turnover is 1.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.55.
Conclusion
To wrap up, the performance of BioAffinity Technologies Inc (BIAF) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
